Imane Nafia

Chief Scientific Officer

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Imane Nafia is the Chief Scientific Officer at Immusmol SAS / Explicyte in France. Her research focuses on immunotherapy and cancer resistance mechanisms, particularly in glioblastoma and non-small cell lung cancer. Notable contributions include studies on enzyme inhibitors and biomarkers that improve treatment outcomes in cancer patients. Her recent publications emphasize the role of immune checkpoint inhibitors and tumor microenvironment interactions in cancer therapy.

Articles (9)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Benjamin Besse

Université Paris-Saclay

FRANCE

View details

Mariella Spalato Ceruso

Institut Bergonié

FRANCE

View details

Medhi Wangpaichitr

Associate Professor

University of Miami Miller School of Medicine

UNITED STATES

View details

Cheng-Bang Chen

Assistant Professor

University of Miami

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Imane Nafia

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.

TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer

TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

IDO Targeting in Sarcoma: Biological and Clinical Implications

Collaborators (4)

Benjamin Besse

Mariella Spalato Ceruso

Medhi Wangpaichitr

Cheng-Bang Chen

Make your next move.